Quick Takeaways:
- Elanco has received USDA approval for TruCan Ultra Lyme-L4, the first and only 0.5 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis. The vaccine combines protection against two significant canine infectious diseases into a single injection, reducing the number of shots required during wellness visits while maintaining the same coverage as Elanco’s 1 mL formulation.
- TruCan Ultra Lyme-L4 incorporates Elanco’s PureFil Technology, which is designed to reduce vaccination reactions associated with unwanted proteins. By combining Lyme and leptospirosis protection into one low-volume dose, the vaccine aims to support a more comfortable vaccination experience for pets while helping veterinarians simplify preventive care protocols.
- The approval comes as leptospirosis continues to be recognized as a core canine vaccine and Lyme disease risk expands into new geographic regions. Elanco noted that a substantial proportion of at-risk dogs remain unvaccinated against Lyme disease despite receiving core vaccines. TruCan Ultra Lyme-L4 joins the company’s growing portfolio of low-volume vaccines, including TruCan Ultra B (Oral) and TruCan Ultra CIV H3N2/H3N8, with commercial shipments expected to begin within the next 30 days.
Why It Matters?
Elanco is tightening its premium position in canine vaccines by launching the first 0.5 mL combo shot that covers both Lyme disease and leptospirosis in a single, low-volume dose, using its PureFil technology to support fewer reactions and more comfortable visits. It will help vets close the vaccination gap in at-risk dogs that get core shots but skip Lyme, by making protection easier to administer.
Source: PRnewswire
